Evolution of the Average Target: Omeros Corporation

Evolution of the Target Price: Omeros Corporation

Changes in Analyst Recommendations: Omeros Corporation

65d295cb9a42d457cb94e6d81e13.m9Z4C6EQ2jddtlGxjn-CK8fARmBqVqssCH59vkhKRoA.-KcyMulXinAo0TDQthL1T_SQBFQFZ_J9XR0X1QEANsPCoC5N-3m7XAvXEA~88e7de0d7f7c70dd34a29e6df7270507
15/10/25 Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk MT
10/06/25 HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target MT
15/03/23 UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating MT
08/12/22 UBS Downgrades Omeros to Neutral From Buy, Adjusts Price Target to $2 From $12 MT
09/11/22 BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3 MT
08/06/22 BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target MT
18/01/22 Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating MT
19/10/21 Omeros : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Rating MT
15/10/21 Omeros : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, Maintains Buy Rating MT
11/10/21 Omeros : Wedbush Suspended Coverage on Omeros MT
08/10/21 Omeros : JPMorgan Downgrades Omeros to Underweight from Neutral MT
06/10/21 Omeros : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating MT
04/10/21 Omeros : Maxim Downgrades Omeros to Hold from Buy MT
01/10/21 Omeros : Wedbush Downgrades Omeros to Underperform From Neutral, Lowers PT to $5 From $18 After FDA Delays PDUFA For Narsoplimab MT
01/10/21 Omeros : Maxim Group Downgrades Omeros to Hold From Buy MT
27/09/21 Omeros : JPMorgan Starts Omeros at Neutral With $15 Price Target MT
18/06/21 Omeros : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target MT
26/04/21 Omeros : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating MT
01/02/21 Omeros : UBS Starts Omeros at Buy With $25 Price Target MT
20/01/21 Omeros : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy Rating MT
20/01/21 Omeros : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral Rating MT
04/12/20 Omeros : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating MT
17/11/20 Omeros : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +72.59%
+19.65%
+16.26%
+60.29%
+20.86%
+17.06%
+13.34%
-0.55%
+26.73%
-6.91%
Average +23.93%
Weighted average by Cap. +20.21%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
19.12USD
Average target price
33.00USD
Spread / Average Target
+72.59%
High Price Target
33.00USD
Spread / Highest target
+72.59%
Low Price Target
33.00USD
Spread / Lowest Target
+72.59%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. OMER Stock
  4. Consensus Omeros Corporation
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!